Aileron Therapeutics fails to regain Nasdaq bid price compliance; granted extension to Dec 5, 2022

Rein Therapeutics, Inc.

Received deficiency notice Dec 2021 for bid price below $1.00; initial 180-day period ended June 6, 2022 without compliance.
Nasdaq granted additional 180-day period until Dec 5, 2022 to cure, conditional on meeting other listing requirements.
Company intends to cure deficiency by effecting a reverse stock split if necessary.
If compliance not achieved by Dec 5, 2022, Nasdaq will issue delisting notification; Company may appeal to Listing Qualifications Panel.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.